Hawaii's Medical Marijuana Card Registration Resource
Big Pharma Getting in the Cannabis Game
May 25, 2017
Per EWN, "GW Pharmaceuticals is set to file its cannabis-derived drug with United States regulators imminently, following publication of detailed data on its success in fighting severe childhood epilepsy.GW first reported in March 2016 that Epidiolex cut monthly convulsive seizures by 39% in children with Dravet syndrome, but full results of the 120-patient study were only published in the New England Journal of Medicine on Wednesday. The journal article also showed that 5% of patients stopped having seizures altogether and 43% saw their seizures cut by half.GW's medicine, which is given as a syrup, is a purified form of cannabidiol, one of the active ingredients found in marijuana. It contains less than 0.1% of tetrahydrocannabinol, the substance that makes people high."